A practical reference on PNB-0408: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Upon his return to the United States in 1973, he became deputy commander for operations at George Air Force Base, California. In 1974 he was assigned as vice commander at Nellis Air Force Base, Nevada, where he flew as an aggressor pilot. He then transferred to Tactical Air Command at Langley Air Force Base in 1975 as director of fighter and reconnaissance operations. In 1976 and 1977 he was assistant to the commander there. Chain became the military assistant to the Secretary of the Air Force in 1978. He then served as deputy director of plans at Air Force headquarters until 1980, when he became director of operations. Chain was assigned as assistant deputy chief of staff for plans and operations in 1981 and became deputy chief of staff for plans and operations in 1982. He served as director of the Bureau of Political-Military Affairs for the Department of State from 1984 until 1985, when he became chief of staff for Supreme Headquarters Allied Powers Europe in Belgium. On July 1, 1985, Chain was promoted to general. In 1986 he became commander in chief of Strategic Air Command, where he oversaw the LGM-118A Peacekeeper operations for the Reagan Administration. He retired from the military on January 31, 1991.
== Further reading == Luig, H.; Kellerer, A. M.; Griebel, J. R. (2011). "Radionuclides, 1. Introduction". Ullmann's Encyclopedia of Industrial Chemistry. doi:10.1002/14356007.a22_499.pub2. ISBN 978-3527306732.
UK and international clinical practice guidelines do not recommend metformin as a first-line treatment or do not recommend it at all, except for people with glucose intolerance. The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from medical treatment. Metformin treatment decreases the risk of developing type 2 diabetes in people with PMOS who exhibited impaired glucose tolerance at baseline. In Poland, metformin is listed as an approved and reimbursed treatment for PMOS.
Sources: en.wikipedia.org
=== Periodicals === International Journal of Food Microbiology Foodborne Pathogens and Disease, ISSN 1535-3141, Mary Ann Liebert, Inc. Mycopathologia, ISSN 1573-0832 (electronic), ISSN 0301-486X (paper), Springer
60th Academy Awards: Best Supporting Actor, nomination, for Street Smart (1987) 62nd Academy Awards: Best Actor, nomination, for Driving Miss Daisy (1989) 67th Academy Awards: Best Actor, nomination, for The Shawshank Redemption (1994) 77th Academy Awards: Best Supporting Actor, win, for Million Dollar Baby (2004) 82nd Academy Awards: Best Actor, nomination, for Invictus (2009) Freeman has been nominated for five Golden Globe Awards, winning one for Best Actor in Driving Miss Daisy (1989). He has also been nominated for three Screen Actors Guild Awards, winning one for Outstanding Performance by a Male Actor in a Supporting Role in Million Dollar Baby (2004). He earned an Obie Award for each theater role in Coriolanus (1979), Mother Courage and Her Children (1980), and Driving Miss Daisy (1987–90).
=== Early studies === Fourteen years after the first publication on its detection in 1973, 12-HHT was reported to stimulate fetal bovine aortic and human umbilical vein endothelial cells to metabolize arachidonic acid to prostaglandin I2 (PGI2 or prostacyclin), a powerful inhibitor of platelet activation and stimulator of vasodilation (see Prostacyclin synthase). 12-HHT did not, however, alter arachidonic acid metabolism in human platelets. Shortly thereafter, 12-HHT was reported to inhibit the chemotaxis-blocking effect of a human monocyte-derived factor on human monocytes. 12-Oxo-HT, the immediate metabolite of 12-HHT, was reported to stimulate the chemotasis of human neutrophils and to inhibit platelet aggregation responses to various agents by stimulating platelets to raise their levels of cyclic adenosine monophosphate (cAMP), an intracellular signal that serves broadly to inhibit platelet activation. These studies were largely overlooked; in 1998 and 2007 publications, for example, 12-HHT was regarded as either inactive or without significant biological activity. Nonetheless, this early work suggested that 12-HHT may serve as a contributor to monocyte- and neutrophil-based inflammatory responses, and that 12-oxo-HT may serve as a counterpoise to platelet aggregation responses elicited or promoted by TXA2.
=== Metabolic actions === Several SIRT2 deacetylation targets play important roles in metabolic homeostasis. SIRT2 inhibits adipogenesis by deacetylating FOXO1 and thus may protect against insulin resistance. SIRT2 sensitizes cells to the action of insulin by physically interacting with and activating Akt and downstream targets. SIRT2 mediates mitochondrial biogenesis by deacetylating PGC-1α, upregulates antioxidant enzyme expression by deacetylating FOXO3a, and thereby reduces ROS levels. Also, Sirt2 can reactivate the inactive G6PD by removing the acetyaltion at K403.
Sources: en.wikipedia.org
Glucose from the bloodstream is taken up by GLUT4 from muscle cells (of the skeletal muscle and heart muscle) and fat cells. GLUT14 is expressed exclusively in testicles. Excess glucose is broken down and converted into fatty acids, which are stored as triglycerides. In the kidneys, glucose in the urine is absorbed via SGLT1 and SGLT2 in the apical cell membranes and transmitted via GLUT2 in the basolateral cell membranes. About 90% of kidney glucose reabsorption is via SGLT2 and about 3% via SGLT1.
In 1957, Boyd Orr served as president of the Second International Humanist Congress, and contributed to the 1968 volume The Humanist Outlook alongside many other prominent humanists. In 1960 Boyd Orr was elected the first president of the World Academy of Art and Science, which was set up by eminent scientists of the day concerned about the potential misuse of scientific discoveries, most especially nuclear weapons. Along with Albert Einstein, Orr was one of the sponsors of the Peoples' World Convention (PWC), also known as Peoples' World Constituent Assembly (PWCA), which took place in 1950–51 at Palais Electoral, Geneva, Switzerland. He was also one of the signatories of the agreement to convene a convention for drafting a world constitution. As a result, for the first time in human history, a World Constituent Assembly convened to draft and adopt the Constitution for the Federation of Earth. Boyd Orr was a member of Bertrand Russell's Who Killed Kennedy? Committee which challenged the official version of the assassination of John F. Kennedy.
Pakistani officials also added that they had destroyed an ammunition depot and headquarters of 205 Corps brigade headquarters in Kandahar. According to Afghan local sources, Taliban were moving tanks, military equipment, and weapons from Takhar and Badakhshan to Kabul amid the conflict with Pakistan. They further add that outposts and checkpoints in parts of northern Afghanistan had been evacuated following the redeployment of Taliban forces from these areas to border regions. UN High Commissioner for Refugees (UNHCR) state that an estimated 115,000 people in Afghanistan and around 3,000 people in Pakistan have been displaced as result of border clashes. Afghans in several cities sent pictures and messages to an Afghan media outlet saying that they were threatened and forced by Taliban to participate in demonstration against Pakistan. Some Afghans in Bamyan province said local businessmen were warned that if they did not participate in the protests, "their shops would be sealed." On 6 March, armed clashes resumed along the border between Taliban forces and Pakistani border guards. Taliban officials said that they had launched an attack on Kharlachi border crossing in Dandpatan district of Paktia province, while sharing pictures of their attack. The Taliban-led Afghan Ministry of Defense said, over the previous 24 hours, Taliban forces had attacked 28 locations in the border areas of Kandahar, Nangarhar, Kunar, Khost, Paktia, and Paktika provinces, killing 109 Pakistani soldiers and injuring 148 others.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.